Assessment of Median and Mean Survival Time in Cancer Clinical Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessment of Median and Mean Survival Time in Cancer Clinical Trials

Published:2023-04-03 Issue:4 Volume:6 Page:e236498
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Das Ananya¹,Lin Timothy A.²,Lin Christine¹,Meirson Tomer³,McCaw Zachary R.⁴,Tian Lu⁵,Ludmir Ethan B.¹

Affiliation:

1. The University of Texas MD Anderson Cancer Center, Houston

2. Johns Hopkins University School of Medicine, Baltimore, Maryland

3. Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel

4. Insitro, South San Francisco, California

5. Department of Health Research and Policy, Stanford University, Stanford, California

Abstract

This cohort study assesses the relative stability of median and mean survival time estimates reported in cancer clinical trials.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2802989/das_2023_ld_230042_1679579384.50269.pdf

Reference6 articles.

1. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.;Uno;J Clin Oncol,2014

2. Pitfall in the design and analysis of comparative oncology trials with a time-to-event endpoint and recommendations.;McCaw;J Natl Cancer Inst Cancer Spectr,2022

3. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio.;Pak;JAMA Oncol,2017

4. Median survival or mean survival: which measure is the most appropriate for patients, physicians, and policymakers?;Ben-Aharon;Oncologist,2019

5. Transparency in reporting of phase 3 cancer clinical trial results.;Patel;Acta Oncol,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3” by M. P. Goetz et al.;Annals of Oncology;2024-08

2. MEDi-SOL: Multi Ensemble Distribution Model for Estimating Sleep Onset Latency;IEEE Journal of Biomedical and Health Informatics;2024-07

3. Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitors in chronic lymphocytic leukaemia;Leukemia;2024-06-01

4. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials;The Oncologist;2024-06-01

5. Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time;British Journal of Cancer;2024-05-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3